Turn innovation into global healthcare impact
Export life science globally
- Expand globally
- Industries
- Export life science
Export opportunities in life science
Exporting life science solutions means operating in highly regulated markets where success depends on clinical evidence, regulatory approvals and effective market access strategies. Opportunities include:
- Pharmaceuticals and advanced therapies
Growing demand for innovative treatments, vaccines and advanced therapies creates opportunities for companies to enter new markets and address future healthcare needs. - Medical technology and diagnostics
Investments in more efficient diagnostics, treatment and patient care create opportunities for companies offering medical technology and diagnostic solutions. - Biotechnology and research tools
Increased investment in research and drug development is driving demand for laboratory equipment, research platforms and specialised tools. - Digital health and connected care
Healthcare digitalisation creates opportunities for companies offering telemedicine, remote monitoring and data-driven solutions that improve access to care. - Partnerships and licensing-based business models
Licensing agreements and strategic collaborations create opportunities to access regulatory expertise, distribution channels and new markets. - Growing global demand for healthcare solutions
An ageing population, rising rates of chronic disease and increasing healthcare investment are driving long-term demand for innovative treatments, technologies and services.
Contact our teeam
Export markets
Export conditions in life science vary significantly across regions, shaped by differences in regulatory frameworks, reimbursement systems, healthcare structures and stakeholder expectations. Understanding how approval processes, market access requirements and partnership models differ is key to prioritising markets and positioning your solutions effectively. With teams on the ground, we provide insight into regulatory conditions, payer systems and local stakeholder landscapes.
Explore our market pages to better understand business opportunities, market conditions, and developments across key regions.
Common challenges
• Regulatory approval and compliance complexity
• Customs procedures and import requirements
• Reimbursement and market access barriers
• Long development and sales cycles
• Need for clinical evidence and local validation
• Building trust with partners and stakeholders
These challenges highlight the need for structured planning and market-specific strategies when expanding internationally.
How we support your export journey
Explore our offeringOur latest reports & insights
All our reportsUpcoming events related to life science
See more eventsSweden Indonesia Sustainability Partnership Week
In 2025, the program goes into the deal pursuit phase, focusing on qualifying and pursuing large-scale healthcare projects with business potential for the participating companies.
Swedish Delegation to BIO-Korea
Opportunity for Swedish companies to showcase innovative technology and explore business collaborations in conjunction with Bio Korea 2025. The overarching goal of this event is to introduce...
Sweden-US Life Science Programme at J.P. Morgan Week 2026
Join Team Sweden in San Francisco this January for one of the world’s largest life science event.
How we support Life science companies
See more client cases
Looking to invest in Sweden?
Sweden offers a competitive life science ecosystem with strong research, data infrastructure and healthcare collaboration. Explore investment opportunities in pharmaceuticals, medtech and digital health innovation.
Frequently asked questions
What types of companies do you support?
We support companies across pharmaceuticals, biotechnology, medical technology, diagnostics and digital health.
Do life science exports require partnerships?
Partnerships are often essential to access regulatory expertise, distribution and customers in international markets.
How important is regulatory approval?
Regulatory approval is a prerequisite for market entry in most countries and often requires significant time and resources.
What are the main barriers to international growth?
Regulation, reimbursement, long timelines and the need to build trust are common challenges.
Do solutions need to be adapted for each market?
Yes, adaptation to local regulatory, clinical and commercial conditions is often required.